Grifols shares rise 1.46% early in the morning and mark new annual maximums In the IBEX 35 in the 11,805 euros, exceeding 11,795 euros that came to play yesterday in the intradiary negotiation.
The Hemoderivated Company begins to see the light at the end of the tunnel after the problems that dragged for 2024 for the attack of the Gotham City Research Background and the doubts about its indebtedness ratios. In this 2025 the waters run much quieter, with an accumulated rise so far in the exercise of 27.6%.
More notable perhaps it is the fact that Grifols shares have already risen 61% since April 7 marked annual minimums at 7,324 euros.
And analysts consider that the company still has a room to fly in the stock market. Today experts from Barclays They have raised the target price of Grifols to the 15 euros per sharefrom the previous 13 euros. Using yesterday’s closure, the new assessment is a Alcista potential of 28.9%while with respect to the current price is 27%.
Despite the improvement, Barclays is not one of the most optimistic analysis houses on value. According to the data collected by Reuters, on average the analysts who cover Grifols give him advice of ‘comprar‘And an objective price of 15,19 euros which is 28.7% above the current price.
Grifols plans to publish its results from the second quarter of the year Next July 29 at the close of the market.